Analyst Price Target is $0.85
▲ +19.25% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for NovaBay Pharmaceuticals in the last 3 months. The average price target is $0.85, with a high forecast of $0.85 and a low forecast of $0.85. The average price target represents a 19.25% upside from the last price of $0.71.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in NovaBay Pharmaceuticals.
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Read More
